标题
Neoadjuvant Immuno-Chemotherapy: A New Perspective for Stage III NSCLC?
作者
关键词
-
出版物
Frontiers in Surgery
Volume 9, Issue -, Pages -
出版商
Frontiers Media SA
发表日期
2022-04-06
DOI
10.3389/fsurg.2022.843987
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non–Small-Cell Lung Cancer
- (2021) Hossein Borghaei et al. JOURNAL OF CLINICAL ONCOLOGY
- The surgical perspective in neoadjuvant immunotherapy for resectable non-small cell lung cancer
- (2021) Long Jiang et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Outcomes of surgical resection after neoadjuvant chemoimmunotherapy in locally advanced stage IIIA non-small-cell lung cancer
- (2021) Alejandra Romero Román et al. EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY
- Association of Dynamic Changes in Peripheral Blood Indexes With Response to PD-1 Inhibitor-Based Combination Therapy and Survival Among Patients With Advanced Non-Small Cell Lung Cancer
- (2021) Yuzhong Chen et al. Frontiers in Immunology
- Agreement on Major Pathological Response in NSCLC Patients Receiving Neoadjuvant Chemotherapy
- (2020) Annikka Weissferdt et al. Clinical Lung Cancer
- CME Part II: Immune checkpoint inhibitor-related dermatologic adverse events
- (2020) Amaris N. Geisler et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial
- (2020) Catherine A Shu et al. LANCET ONCOLOGY
- Immune-Related Adverse Events (irAEs): Diagnosis, Management, and Clinical Pearls
- (2020) Eli P. Darnell et al. Current Oncology Reports
- Surgery for stage IV non-small cell lung cancer?
- (2020) Carlos A. Puig et al. Journal of Thoracic Disease
- Anti-PD-1-Related Exacerbation of Interstitial Lung Disease in a Patient with Non-Small Cell Lung Cancer: A Case Presentation and Review of the Literature
- (2020) Julie Anne L. Gemmill et al. CANCER INVESTIGATION
- Advances in the Treatment of Stage III Non–Small Cell Lung Cancer
- (2020) Nathaniel J. Myall et al. CLINICS IN CHEST MEDICINE
- Clinicians versus patients subjective adverse events assessment: based on patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE)
- (2020) Lei Liu et al. QUALITY OF LIFE RESEARCH
- Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitor Therapy
- (2020) Adrienne K. Ho et al. ANESTHESIA AND ANALGESIA
- Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial
- (2020) Mariano Provencio et al. LANCET ONCOLOGY
- Tumor-Infiltrating Lymphocytes and Their Prognostic Value in Cutaneous Melanoma
- (2020) Fabienne Maibach et al. Frontiers in Immunology
- Plasma IL-6 changes correlate to PD-1 inhibitor responses in NSCLC
- (2020) Alissa Keegan et al. Journal for ImmunoTherapy of Cancer
- Hyperprogression: A novel response pattern under immunotherapy
- (2020) Xue‐jiao Han et al. Clinical and Translational Medicine
- Biomarkers for Predicting Response to Immunotherapy with Immune Checkpoint Inhibitors in Cancer Patients
- (2019) Michael J. Duffy et al. CLINICAL CHEMISTRY
- The Folate Pathway Inhibitor Pemetrexed Pleiotropically Enhances Effects of Cancer Immunotherapy
- (2019) David A. Schaer et al. CLINICAL CANCER RESEARCH
- Stage III Non-small Cell Lung Cancer Management in England
- (2019) J.B. Adizie et al. CLINICAL ONCOLOGY
- Immune Checkpoint Inhibitor Therapy–related Pneumonitis: Patterns and Management
- (2019) Kevin R. Kalisz et al. RADIOGRAPHICS
- Annual Report to the Nation on the Status of Cancer, part I: National cancer statistics
- (2018) Kathleen A. Cronin et al. CANCER
- Combined blockade of IL-6 and PD-1/PD-L1 signaling abrogates mutual regulation of their immunosuppressive effects in the tumor microenvironment
- (2018) Hirotake Tsukamoto et al. CANCER RESEARCH
- Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: Comparison of RECIST 1.1, irRECIST and iRECIST criteria
- (2018) M. Tazdait et al. EUROPEAN JOURNAL OF CANCER
- Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
- (2018) Patrick M. Forde et al. NEW ENGLAND JOURNAL OF MEDICINE
- Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab
- (2017) Stefan Diem et al. LUNG CANCER
- Management of stage III non–small cell lung cancer
- (2017) Samer Tabchi et al. SEMINARS IN ONCOLOGY
- The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer
- (2016) Peter Goldstraw et al. Journal of Thoracic Oncology
- Surgical management of oligometastatic non-small cell lung cancer
- (2016) Nuria M. Novoa et al. Journal of Thoracic Disease
- Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint
- (2014) Matthew D Hellmann et al. LANCET ONCOLOGY
- Mediastinal Lymph-nodes Metastasis beyond the Lobe-specific: An Independent Risk Factor toward Worse Prognoses
- (2013) Yifeng Sun et al. Annals of Thoracic and Cardiovascular Surgery
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started